Sean Nolan

Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL.

Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC.

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical firm utilizing sophisticated computational methods. develop and designs de novo protein therapeutics. The company was is headquartered in Seattle, WA.

Encoded Therapeutics, Inc. operates as a biotechnology company that engages in the development of precision medicines and therapy for genetic disorders. It focuses on viral gene therapies. The company was founded by Kartik Ramamoorthi and Stephanie Tagliatela and is headquartered in South San Francisco, CA.

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.

Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA.

Jaguar Gene Therapy LLC is a clinical stage biotechnology company based in Lake Forest, IL. Jaguar Gene Therapy LLC is dedicated to accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company has a proven team of experts who have experience in bringing novel gene therapy treatments to patients and their families. Jaguar is rapidly advancing an initial pipeline of three programs, including targeting severe neurodevelopmental disorders, type 1 galactosemia, and type 1 diabetes. The company partner with Advanced Medicine Partners for manufacturing their therapeutics. Key investors include Deerfield Management Company, Arch Venture Partners, and Eli Lilly and Company. The company was founded by Daniel Gallo, and Joseph Nolan has been the CEO since 2020.